Analyst Ratings For bluebird bio (NASDAQ:BLUE)
Today, bluebird bio (NASDAQ:BLUE) stock was downgraded by Leerink Swann from Outperform to Market Perform.
Some recent analyst ratings include
- 1/25/2018-Leerink Swann was Downgraded by analysts at Leerink Swann from a “Outperform ” rating to a ” Market Perform” rating.
- 1/9/2018-Oppenheimer Reiterated Rating of Hold.
- 12/21/2017-CIBC initiated coverage with a Market Perform rating.
- 12/13/2017-Maxim Group was Downgraded by analysts at Maxim Group from a “Buy ” rating to a ” Hold” rating. They now have a $200.00 price target on the stock.
- 12/13/2017-Barclays Reiterated Rating of Overweight .
- 12/12/2017-Wells Fargo & Co Reiterated Rating of Outperform.
- On 1/8/2018 David Davidson, Insider, sold 3,522 with an average share price of $173.61 per share and the total transaction amounting to $611,454.42.
- On 1/5/2018 Jason Cole, Insider, sold 1,129 with an average share price of $173.38 per share and the total transaction amounting to $195,746.02.
- On 1/5/2018 Nick Leschly, CEO, sold 5,435 with an average share price of $173.38 per share and the total transaction amounting to $942,320.30.
- On 1/3/2018 David Davidson, Insider, sold 6,000 with an average share price of $180.30 per share and the total transaction amounting to $1,081,800.00.
- On 12/13/2017 Nick Leschly, Insider, sold 117,500 with an average share price of $184.08 per share and the total transaction amounting to $21,629,400.00.
- On 12/11/2017 Jeffrey T Walsh, Insider, sold 9,900 with an average share price of $216.54 per share and the total transaction amounting to $2,143,746.00.
- On 12/11/2017 Mark Vachon, Director, sold 7,000 with an average share price of $216.64 per share and the total transaction amounting to $1,516,480.00.
Recent Trading Activity for bluebird bio (NASDAQ:BLUE)
Shares of bluebird bio closed the previous trading session at 202.36 down -5.09 2.45% with 204.60000610351562 shares trading hands.
